Another Big Turnout For Second Public Dialogue Of UN High-Level Panel On Medicines Access

Today in Johannesburg, South Africa, the second of two public dialogues was held by the United Nations Secretary General’s High-Level Panel on Access to Medicines, drawing another packed room and many ideas, experiences and suggestions for solutions.

Asia On The Heels Of US And Europe In Patent Applications At WIPO; Developing Countries Lagging

China, Japan and South Korea are among the top five countries filing international patent applications at the World Intellectual Property Organization, while the United States continues to lead in patent and trademark applications. Far behind, developing countries seem to be having a hard time catching up.

US Officials Under Pressure To Include Industry In IP Talks With India

The United States government has increasingly engaged India on intellectual property rights and other trade issues in recent years, and US negotiators are under still more pressure to include industry in this engagement and deliver more results, a recent letter from 14 members of the US Congress shows.

Ukraine To Amend Customs Code, Ratify Amendments To TRIPS

The Ukrainian Parliament is currently drafting an amended Customs Code to introduce a number of changes to the country’s intellectual property legislation. Moreover, in mid-March, local lawmakers authorised Ukraine’s President Petro Poroshenko to ratify the protocol amending the TRIPS agreement which enables increased exports of pharmaceuticals produced under compulsory licences to countries which are not capable of manufacturing them locally.

Changes At Top Of The UN; Recruitment Ongoing

This year will be the last in office for United Nations Secretary General Ban Ki-moon. A number of Eastern European candidates are being proposed by their governments to be the next secretary general. The UN Framework Convention on Climate Change, as well as the UN Environment Programme are expected to have a new head by summer. Meanwhile, chairs are actively revolving in law offices.

China’s Pharmaceutical Sector And The IP Puzzle

Despite impressive growth, the pharmaceutical sector in China still relies on generic drug production since the majority of domestic companies cannot compete with country-based foreign corporations. Currently, following WTO pressure to oblige China to comply with IP regulations, more and more patented drugs are entering the market. Unfortunately, in spite of a newly introduced IP friendly bill, a puzzling situation persists, writes Pietro Dionisio.

US Senators Release Public Comments On Sovaldi Report

Two key senators today released dozens of comments they received in response to their report on the medicine Sovaldi (and its follow-on Harvoni), whose extreme high prices sparked a debate over pharmaceutical pricing that has created momentum for policy changes.